We are live on ! Find out more
DRMA icon

Dermata Therapeutics
DRMA

9 hedge funds and large institutions have $101K invested in Dermata Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.3% less ownership

Funds ownership: 9.25% → 1.95% (-7.3%)

10% less funds holding

Funds holding: 10 → 9 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

82% less capital invested

Capital invested by funds: $554K → $101K (-$453K)

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$46.8K
2
Jane Street
Jane Street
New York
+$15.6K
3
Wells Fargo
Wells Fargo
California
+$7.8K
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.24K
5
UBS Group
UBS Group
Switzerland
+$1.56K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$414K
2
Citadel Advisors
Citadel Advisors
Florida
-$52K
3
Citigroup
Citigroup
New York
-$32K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$7K

DRMA Hedge Fund Activity: Q3 2022 in Review

9 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q3 2022, worth a combined $101K — down 82% from $554K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of DRMA and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $46.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $414K sold.

  • 9 institutional investors held Dermata Therapeutics (DRMA) as of Q3 2022, down from 10 in Q2 2022.
  • Funds reported $101K of Dermata Therapeutics stock for Q3 2022, down 82% quarter-over-quarter.
  • 3 funds opened new Dermata Therapeutics positions in Q3 2022 and 4 closed out, a net change of -1 holder.
  • The largest Dermata Therapeutics buyer in Q3 2022 was Virtu Financial, an estimated $46.8K added.
  • The largest Dermata Therapeutics seller in Q3 2022 was Armistice Capital, an estimated $414K sold.

Based on aggregated 13F filings for Q3 2022.